BRVE

Braveheart Bio Inc

19.46

Nov 09 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: CYTK EWTX MLYS NAMS TNYA BMY BBIO LXEO VERA TRVI

| Held by: VTI VXF SCHA ONEQ SCHB VTWO FMED TMED VTWG VTWV

Index	-
Market Cap	1.75B
Enterprise Value	1.84B
Income	-
Sales	-
Book/sh	-1.07
Cash/sh	1.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 06, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	14.27
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.63
Current Ratio	13.63
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.44
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 08 AMC
EPS/Sales Surpr.	-193.45% -

Insider Own	76.55%
Insider Trans	14.70%
Inst Own	0.36%
Inst Trans	20.17%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.26%
SMA50	-13.75%
SMA200	-18.32%
Trades

Shs Outstand	90.04M
Shs Float	21.11M
Short Float	23.24%
Short Ratio	10.77
Short Interest	4.91M
52W High	32.00 -39.19%
52W Low	16.70 16.53%
Volatility	11.59% 7.68%
ATR (14)	1.70
RSI (14)	43.42
Beta	-
Rel Volume	0.00
Avg Volume	455.44K
Volume	0

Perf Week	-7.51%
Perf Month	-2.80%
Perf Quarter	-22.19%
Perf Half Y	-
Perf YTD	-35.56%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	45.25
Prev Close	19.46
Price	19.46
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$45.25

Implied Upside

+132.5%

Analysts5incl. previous ratings

Rating Distribution5 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 31, 2026	Initiated	TTD Cowen	Buy
Aug 31, 2026	Initiated	SStifel	Buy	$45	+131.2%
Aug 31, 2026	Initiated	JJefferies	Buy	$48	+146.7%
Aug 31, 2026	Initiated	GGoldman	Buy	$48	+146.7%
Aug 31, 2026	Initiated	CCantor Fitzgerald	Overweight	$40	+105.5%

Nov-09-26 07:30AM	Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-06-26 03:15PM	Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 (GlobeNewswire) +6.80%
Nov-03-26 06:15AM	How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks (Barrons.com)
Oct-30-26 07:30AM	Braveheart Bio to Host Webinar - HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor - with Key Opinion Leader Discussion on November 6, 2026 (GlobeNewswire)
07:30AM	Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026 (GlobeNewswire)
04:30PM	Loading…
Sep-16-26 04:30PM	Braveheart Bio to Participate in Stifel Cardiometabolic Forum (GlobeNewswire)
Sep-08-26 04:03PM	Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +9.99%
Sep-01-26 04:30PM	Braveheart Bio to Participate in Cantor Global Healthcare Conference (GlobeNewswire)
Aug-31-26 09:45AM	Deere upgraded, Lumentum initiated: Wall Street's top analyst calls (The Fly) -7.07%
07:00AM	Jefferies starts biopharma firm Braveheart at Buy after IPO (Investing.com)
Aug-07-26 04:05PM	Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.23%

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AH Bio Fund IV, L.P.	10% Owner	Aug 07 '26	Buy	18.00	1,100,000	19,800,000	10,232,420	Aug 11 05:53 PM
Chimovits Erez	Director	Aug 07 '26	Buy	18.00	1,940,000	34,920,000	11,901,826	Aug 11 05:31 PM
ORBIMED ADVISORS LLC	Director	Aug 07 '26	Buy	18.00	1,940,000	34,920,000	11,901,826	Aug 11 05:27 PM
Forbion Growth Opportunities F	10% Owner	Aug 07 '26	Buy	18.00	1,920,000	34,560,000	11,640,546	Aug 07 05:25 PM
Forbion Growth Opportunities F	10% Owner	Aug 07 '26	Buy	18.00	1,680,000	30,240,000	10,185,478	Aug 07 05:25 PM
Rickey James Paul	Chief Financial Officer	Aug 07 '26	Buy	18.00	27,777	499,986	520,927	Aug 07 04:41 PM
Viehbacher Christopher	Director	Aug 07 '26	Buy	18.00	83,333	1,499,994	609,519	Aug 07 04:31 PM
Malek David I	Director	Aug 07 '26	Buy	18.00	4,166	74,988	533,845	Aug 07 04:31 PM
Anderson Michele A.	Chief Development Officer	Aug 07 '26	Buy	18.00	1,111	19,998	332,161	Aug 07 04:30 PM
Murdoch Travis	CEO and President	Aug 07 '26	Buy	18.00	83,333	1,499,994	2,940,670	Aug 07 04:30 PM
Lubner David Charles	Director	Aug 07 '26	Buy	18.00	55,555	999,990	55,555	Aug 07 04:30 PM

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

M.D.Dr. Travis Murdoch B.S.

Chief Financial OfficerMr. James Paul Rickey CPA

Chief Development OfficerMs. Michele A. Anderson

Chief Scientific OfficerMr. Marc Evanchik M.S.

VP & Head of LegalMs. Natalie Dement J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BRVE

Braveheart Bio Inc

Upgrade your Finviz experience